5 Mar 2021 Share:
As the world considers strategies towards Zero COVID , research specialists also continue to work on eliminating the many other infectious diseases we have learned to live with . Now, new research provides important insight into the challenges that remain in the fight for Zero Leprosy . Mathematical modelling has been applied to direct policy development in the control and elimination of this ancient chronic infectious disease that still affects a substantial number of people.
To interrupt leprosy transmission and reduce annual new cases significantly, preventive treatment needs to be implemented in all leprosy-endemic countries. A 50% reduction of new leprosy cases could be achieved in five years according to new mathematical models.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Merus Announces Collaborations with Nationwide Medical Organizations in the Netherlands and .
Merus N.V.January 12, 2021 GMT
UTRECHT, The Netherlands, and CAMBRIDGE, Mass., Jan. 12, 2021 (GLOBE NEWSWIRE) Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™), today announced collaborations with nationwide medical organizations in the Netherlands and Japan to raise awareness of the eNRGy trial and to provide molecular screening opportunities for patients with cancers that may have neuregulin 1 (NRG1) fusions. In the collaborations, Merus has agreed to support access to next generation sequencing for eligible patients with pancreatic adenocarcinoma in the Netherlands, and pancreatic adenocarcinoma and non-small cell lung cancer (NSCLC) in Japan, aimed to identify the presence of NRG1 fusio